Supernus Pharmaceuticals, Inc. provided earnings guidance for the year 2024. For the year, the company expects total revenues (includes approximately $125 - $135 million of Trokendi XR and Oxtellar XR) of $580 million - $620 million, and Operating loss of $30 million - $0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.3 USD | +0.48% | +4.06% | +8.15% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.15% | 1.71B | |
+6.97% | 71.94B | |
-10.86% | 5.13B | |
+46.43% | 4.66B | |
+5.38% | 3.97B | |
-16.20% | 2.55B | |
+21.10% | 2.41B | |
-26.20% | 2.36B | |
+19.92% | 2.21B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024